The 5th U.S. Circuit Court of Appeals issued a unanimous ruling Friday that blocks mail-order access to the abortion pill mifepristone across the country, a decision that immediately prompted the drug’s manufacturers to ask the Supreme Court to intervene. The ruling, which requires mifepristone to be dispensed only in person at clinics, overrides regulations the Food and Drug Administration had put in place, and it represents the most significant federal court restriction on medication abortion since the Supreme Court overturned Roe v. Wade in 2022.
The case originated from a lawsuit filed last year by Louisiana Attorney General Liz Murrill, who argued that the FDA’s mail-order rules undermined the state’s near-total abortion ban. The appellate court’s decision, however, applies nationally — not only to states with bans — and affects patients even in places where abortion remains legal. “This is a huge access issue for patients that haven’t got providers close by, or providers close by who are willing to prescribe,” said Josh Thorburn, owner of Eddie’s Pharmacy in Los Angeles.
Medication abortion has become the most common method in the United States, with surveys showing that the majority of abortions use pills and roughly one in four are prescribed via telehealth. Providers and researchers have suggested that the wide availability of mifepristone by mail is a major reason why the national abortion rate has not declined since the end of Roe. The 5th Circuit ruling, by mandating in‑person dispensing, directly threatens that telehealth infrastructure. Mini Timmaraju, president and CEO of Reproductive Freedom for All, said providers are “in limbo” as they await further court decisions but can pivot to using the secondary drug misoprostol, which is less effective on its own.
Some Democratic-led states have enacted shield laws intended to protect clinicians who mail abortion pills into states with bans. Dr. Angel Foster, who directs The Massachusetts Medication Abortion Project, said her organization was consulting legal experts to understand the ruling’s impact. “We will do everything in our power to continue providing care to people in all 50 states,” she said.
There is little precedent for a federal court overriding the FDA’s scientific regulations. Ziegler, the UC Davis law professor, said the appellate ruling “injects immediate confusion and upheaval into highly time-sensitive medical decisions” and noted that the outcome could be “as significant as anything we’ve seen since Roe was overturned.” She predicted the case would again make abortion a central issue in the midterm elections. “Another big question mark is going to be the extent to which voters feel that before they go to the polls,” she said.
Electoral history supports that assessment: since Roe fell, abortion-related questions have been on the ballot in 17 states, and voters have sided with the abortion-rights position in 14 of those contests. Fatima Goss Graves, president of the National Women’s Law Center, called the ruling “deeply out of step with both the public and fact-based science.”
The ruling also pressures President Donald Trump, who drew criticism from anti-abortion advocates after his administration approved a generic version of mifepristone last year. Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, said “it’s shameful that the Trump administration’s inaction has forced pro-life states to take their battle to the federal courts,” while also applauding the appellate ruling. The White House and the FDA did not immediately respond to requests for comment.